obesity

Orexigen Safety Study for Diet Pill Ends due to Premature Data Disclosure
WSJ Pharmalot
Tue, 05/12/15 - 04:20 pm
Orexigen
Contrave
obesity
Vivus - Qsymia Script Sales Flat Again - Should Vivus Concentrate On Stendra?
Seeking Alpha
Sat, 05/9/15 - 12:19 pm
Vivus
Qsymia
Stendra
obesity
erectile dysfunction
What Novo Nordisk's Entry Into The Obesity Space Means To The Sector
Seeking Alpha
Fri, 04/24/15 - 11:03 am
Novo Nordisk
obesity
Saxenda
Arena - Belviq Scripts Down: Competition, Or Lack Of Commitment From Partner Eisai?
Seeking Alpha
Fri, 04/24/15 - 09:20 am
Eisai
Arena Pharmaceuticals
Belviq
obesity
Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month
Fierce Pharma
Wed, 04/22/15 - 01:55 pm
Novo Nordisk
Saxenda
obesity
Analyst: Vivus generic threats a positive for obesity market
Fierce Pharma
Fri, 04/17/15 - 10:35 am
Vivus
obesity
generics
Qsymia
Teva Pharmaceuticals
Actavis
Arena's 15,000 Scripts Set Pace Vs. Competitors
Seeking Alpha
Mon, 04/13/15 - 06:03 pm
Arena Pharmaceuticals
Orexigen
obesity
Belviq
Contrave
Novo Nordisk Quietly Becoming Big Player In Obesity Space
Seeking Alpha
Fri, 04/10/15 - 09:27 am
Novo Nordisk
obesity
Saxenda
EXCLUSIVE: FDA says ReShape Medical can skip advisory panel for obesity balloon device
Mass Device
Wed, 04/8/15 - 10:18 am
FDA
ReShape Medical
advisory panels
obesity
Orexigen says EU regulators approved its weight loss drug, which will be marketed as Mysimba
Yahoo/AP
Thu, 03/26/15 - 09:32 pm
Orexigen
Europe
obesity
Mysimba
Contrave
Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?
Seeking Alpha
Tue, 03/24/15 - 08:30 am
Vivus
Orexigen
Arena Pharmaceuticals
Contrave
Belviq
Qsymia
obesity
Obesity medications still a hard sell
Medical Marketing and Media
Tue, 03/17/15 - 07:15 pm
obesity
Arena's Belviq Slows At A Bad Time
Seeking Alpha
Tue, 02/24/15 - 09:57 am
Arena Pharmaceuticals
Belviq
obesity
Weight loss pacemaker company Enteromedics gearing up for commercial launch
Mass Device
Mon, 02/23/15 - 11:18 am
EnteroMedics
devices
Maestro implant
obesity
Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
TheStreet.com
Sat, 02/21/15 - 09:44 am
obesity
Orexigen
Arena
Vivus
Belviq
Contrave
Qsymia
Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion
Seeking Alpha
Wed, 02/18/15 - 10:52 am
Vivus
Qsymia
obesity
Orexigen
Arena Pharmaceuticals
Contrave
Belviq
Orexigen: Contrave Scripts Slow Down - Competition Lowers Price
Seeking Alpha
Tue, 02/3/15 - 09:01 am
Orexigen
Contrave
obesity
Arena's Belviq Sales Need Better Pace
Seeking Alpha
Tue, 02/3/15 - 08:56 am
Arena Pharmaceuticals
Belviq
obesity
Arena - Flat Scripts Is Not A Good Start To 2015
Seeking Alpha
Wed, 01/28/15 - 08:06 am
Arena Pharmaceuticals
Eisai
Belviq
obesity
Contrave
Orexigen
Arena's Sales Pace For Belviq - What Is Needed
Seeking Alpha
Thu, 01/22/15 - 09:45 am
Arena Pharmaceuticals
Belviq
obesity

Pages